- Recipharm announces a major investment in its Zwickau, Germany facility, adding new GMP pilot scale suites.
- The new pilot scale center for dry technologies is set to be GMP-ready by Q1 2025.
Recipharm, a global pharmaceutical contract development and manufacturing organization (CDMO), has revealed plans to invest significantly in its Oral Solid Development and Pilot Scale Center located in Zwickau, Germany. The investment includes the addition of three new GMP pilot scale suites designed for blending, tableting, and hard capsule filling.
The newly introduced facilities will feature a pilot scale hard capsule filler equipped with dual filling and mini tablet dosing capabilities, a Style One EVO Compression and Compaction Simulator, and a pilot scale tablet press. This expansion is expected to enhance Recipharm’s capabilities in dry granulation and tableting.
The new pilot scale centre is projected to be GMP-ready by the first quarter of 2025. This development aligns with the recent launch of ReciPredict, a pharmaceutical platform developed by Recipharm. ReciPredict employs data science and modelling to streamline drug development, reduce costs, and ensure consistent product quality.
Dr. Uwe Hanenberg, PhD, Head of Product Implementation at Recipharm, stated, “With these advancements, we can now offer late-stage product development, clinical supply, and commercial manufacturing from a single site. This integration makes it more efficient and cost-effective for our customers, providing them with access to top experts, while ensuring efficiencies in material consumption, including APIs.”
The new capabilities at Recipharm’s Zwickau site will support a range of services including API and excipient characterization, product and process development, and clinical supply, aiming to deliver a faster clinic-to-market timeline for new drugs.
 Overview of outsourcing trends 
